A study of pembrolizumab and usual treatment for cervical cancer (The Papaya Study)

Cancer type:

Cervical cancer

Status:

Results

Phase:

Phase 1

This study looked at whether pembrolizumab could improve treatment for cancer of the cervix.

More about this trial

Doctors often treat cervical cancer with a combination of chemotherapy and radiotherapy. This is called chemoradiation. It is standard treatment for cervical cancer. 
 
But sometimes the cancer continues to grow. So, researchers are looking for ways to improve treatment. In this study they looked at a drug called pembrolizumab.
 
Pembrolizumab is a type of immunotherapy It works by helping the immune system to recognise and attack cancer cells. 
 
The main aims of this study were to:
  • see if adding pembrolizumab to standard treatment keeps the cancer under control for longer
  • learn more about the side effects

Summary of results

It was difficult to get enough women to join the trial. So the trial was never finished and there are no results available. 

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Susan Lalondrelle

Supported by

Biomedical Research Centre (BRC)
Merck, Sharpe & Dohme
Royal Marsden NHS Foundation Trust

 

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

15406

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think